Another No For Vertex As Scotland Rejects Offer For Orkambi And Symkevi
The Scottish Medicines Consortium has issues over the price Vertex Pharmaceuticals is asking for its cystic fibrosis drugs, and like NICE in England it has rejected the products for use on the National Health Service.
You may also be interested in...
Vertex has managed to secure a deal to provide Scottish cystic fibrosis patients with access to Orkambi and Symkevi. The promise of real world data and a price discount has convinced the Scottish government to say yes to the treatments, which had earlier been rejected by the Scottish Medicines Consortium.
The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory licensing.
Vertex has come under fire for its alleged extreme rigidity on pricing for its cystic fibrosis drug in England.